Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection

Next Previous
Search
Trial Profile

Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarilumab (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia; Severe acute respiratory syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SARCOVID

    • Most Recent Events

    • 09 Nov 2021 Primary endpoint (Median (IQR) change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation) has not been met as per results presented at the ACR Convergence 2021
    • 09 Nov 2021 Primary endpoint (Death) has not been met as per results presented at the ACR Convergence 2021
    • 09 Nov 2021 Primary endpoint (Duration of hospitalisation (days)) has not been met as per results presented at the ACR Convergence 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top